Physician profile

Robert Ching Chan

Urogynecology and Reconstructive Pelvic Surgery (Urology) · Greenbrae, CA

NPI 1295980647

$13,772.43

in general payments reported to CMS, 2019-2025

43 companies · $1,053 in 2025

The $1,053 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$3,992.84

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Coloplast Corp $6,258.41 2019-2023 Porges Coloplast, Altis
Axonics, INC. $1,136.21 2021-2024 Axonics
Sumitomo Pharma America, INC. $953.83 2023-2025 Gemtesa, Orgovyx
Boston Scientific Corporation $858.51 2019-2025 Rezum Generator, Spaceoar Vue System - 10ml, Axonics
Neotract INC. $719.39 2019-2020
Abbvie INC. $593.61 2019-2025 Botox, Lupron Depot
Astellas Pharma US INC $416.87 2019-2024 Myrbetriq, Veozah
Janssen Biotech, INC. $346.64 2019-2025 Rybrevant, Carvykti
Laborie Medical Technologies Corp. $180.29 2024-2025 Optilume Bph Drug Coated Balloon Catheter, Eclipse
Pfizer INC. $170.86 2019-2025
C. R. Bard, INC. & Subsidiaries $165.82 2022-2025 Bard Urinary Drainage Bag
Allergan, INC. $153.19 2019-2021
Dornier Medtech America, INC $144.98 2022
Ambu INC. $143.33 2021-2024
Astellas Pharma Global Development $129.88 2024 Xtandi
Show all 43 companies
CompanyGeneral paymentsYearsTop products
Endo Pharmaceuticals INC. $128.36 2023 Xiaflex, Aveed, Edex
Ferring Pharmaceuticals INC. $124.96 2024 Adstiladrin
Ethicon US, LLC $101.52 2025 Vistaseal, Stratafix
Edap Technomed INC $100.00 2023
Rochester Medical Corporation $84.41 2020-2022
Telix Pharmaceuticals $76.78 2024-2025 Illuccix
Olympus America INC. $76.58 2022-2025 Itind System
Becton, Dickinson and Company $70.54 2024 Bard Urinary Drainage Bag
Biotissue Holdings INC. $66.24 2024-2025
Smith+Nephew, INC. $63.25 2023-2025 Stravix
Blue Earth Diagnostics $54.61 2023
Urogen Pharma, INC. $52.82 2021-2025
Endo USA, INC. $41.40 2024 Xiaflex
Davol INC. $37.83 2025 Arista
Tolmar, INC. $29.85 2023
Convatec INC. $29.52 2024
Caldera Medical, INC $27.50 2022
180 Medical, INC. $25.22 2024 Cure Catheter
Vertex Pharmaceuticals Incorporated $24.95 2025
Therapeuticsmd, INC. $24.37 2019
Progenics Pharmaceuticals, INC. $23.41 2025
Avadel Specialty Pharmaceuticals, LLC $23.00 2019
Teleflex LLC $21.41 2022
Abbott Laboratories $20.68 2021
Halozyme INC $19.58 2023
Dentsply Ih Ab $17.85 2023 Lofric
Sagent Pharmaceuticals $17.60 2022
Dendreon Pharmaceuticals LLC $16.37 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert Ching Chan

$13,772.43

in general payments reported 2019-2025

Years
2019-2025
Top company
Coloplast Corp
Context
The $1,053 reported for 2025 was more than what a typical Urogynecology and Reconstructive Pelvic Surgery (Urology) provider received nationally (typical 2025 total: $782).

https://glasscript.com/doctor/149883/robert-ching-chan

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.